Characterizing Prescribing Patterns of Diabetes Medications at an Adult Medicine Clinic: A Focus on Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors

Type 2 diabetes is highly prevalent in the United States. As of 2021, 38.4 million people (11.6% of the population) are currently living with type 2 diabetes (1). Uncontrolled diabetes can lead to long-term consequences for patients in the form of microvascular and macrovascular complications. Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in these patients, with diabetes itself being an independent risk factor for ASCVD (2). The diagnosis of type 2 diabetes confers a twofold risk of vascular disease, including coronary artery disease and stroke (3). Additionally, 50% of all end-stage renal disease (ESRD) cases worldwide are caused by diabetes (4). Managing patients with type 2 diabetes requires a comprehensive approach that considers these components.